Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adopt this strategy. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adapt this strategy. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To present the analysis of our transplant strategy. Results of the analysis of about 100 transplants is shown. Dr Maria Liga presented us her database. Prof. Spyridonidis explained how the data were analysed. The decision to add Cellcept in the case of a...

Goal: The use of TKIs post transplant to prevent relapse. A recent paper describing how sorafenob in mflt3 mutant AML promotes the local GVL effect is presented.  Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: Our current research paper in CLL published in Blood Advances was presented. Further goals were discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: To learn how to calculate EFS,OS, TRM, how to create Kaplan Meier curves and CI curves. The difference between CI and Kapolan Meier was discussed. Corresponding literature from ALPWP EBMT is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: To learn the differences between RIC, RTC, MAC, NMA, etc. Corresponding literature is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: To learn how to deceide whether we should get an older person to transplant. Literature and cases are presented. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand the structure of donor registries. Learn corresponding terminology. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal:To learn about Bite, inotuzumab and CART therapies. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: Which graft is better to use in haplo PTCY transplant? Dr Liga presented the current literature. We deceide the following policy CR-1 BM, advanced disease PBSC. Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: An overview of the haplo PTCY platform. Presenter: Dr Liga. Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: Principles of Donor selection. Quiz and examples were shown. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou  

Goal: to get an overview of current cellular therapies and learn where we stand. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou

a reent  study publisghed at LEukemia confirms the role of upfront ASCT in MM. Upfornt autolgous is the standrd of care in MM Presenter: Spyridonidis Patriciapnts: all medical staff

The FDA approved tisagenlecleucel (Kymriah) for certain paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL). The cell-based gene therapy is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that...

Combined use of global and targeted analyses allows the cytogenetic classification of 88% of adult patients with Ph-negative BCP-ALL. • In GRAALL trials, t(4;11)/KMT2A-AFF1 and t(v;14q32)/IGH are the two cytogenetic anomalies significantly associated with a worse outcome. Combined use of global and targeted analyses allows the cytogenetic...